Associations between Aquaglyceroporin Gene Polymorphisms and Risk of Stroke among Patients with Hypertension
Table 3
Stratified analysis between the AQP7 gene and the risk of stroke.
Variable
(Control/stroke)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
OR (95% CI)
rs2989924
AA
AG
GG
AA
AG
GG
AA+AG
GG vs. AA+AG
Males
58/18
122/41
68/40
1.00
1.08 (0.57-2.05)
0.71 (0.36-1.43)
1.90 (0.98-3.66)
1.79 (0.90-3.56)
1.37 (0.76-2.48)
1.11 (0.60-2.07)
1.80 (1.10-2.93)
2.23 (1.32-3.77)
Females
59/23
195/45
115/43
1.00
0.59 (0.33-1.06)
0.57 (0.31-1.07)
0.96 (0.53-1.74)
0.99 (0.53-1.85)
0.73 (0.43-1.25)
0.73 (0.41-1.30)
1.40 (0.90-2.17)
1.46 (0.91-2.32)
(years)
52/19
131/40
69/27
1.00
0.84 (0.44-1.58)
0.61 (0.30-1.24)
1.07 (0.54-2.13)
0.86 (0.41-1.80)
0.92 (0.51-1.66)
0.71 (0.37-1.35)
1.21 (0.71-2.07)
1.19 (0.66-2.13)
>60 (years)
65/22
186/46
114/56
1.00
0.73 (0.41-1.31)
0.64 (0.35-1.18)
1.45 (0.81-2.59)
1.62 (0.89-2.95)
1.01 (0.59-1.71)
0.10 (0.58-1.73)
1.81 (1.20-2.75)
2.20 (1.41-3.44)
54/18
168/47
103/33
1.00
0.84 (0.45-1.57)
0.79 (0.40-1.56)
0.96 (0.50-1.86)
1.04 (0.51-2.11)
—
0.89 (0.47-1.67)
—
1.23 (0.73-2.07)
≥25
63/23
149/39
80/50
1.00
0.72 (0.40-1.30)
0.58 (0.31-1.11)
1.71 (0.95-3.10)
1.67 (0.89-3.11)
1.07 (0.62-1.82)
0.97 (0.55-1.71)
2.14 (1.36-3.36)
2.35 (1.45-3.81)
Without central obesity
33/10
73/23
45/20
1.00
1.04 (0.45-2.43)
0.84 (0.34-2.08)
1.47 (0.61-3.54)
1.23 (0.48-3.15)
1.20 (0.55-2.65)
0.99 (0.43-2.29)
1.43 (0.74-2.75)
1.39 (0.68-2.85)
With central obesity
84/31
244/63
138/63
1.00
0.70 (0.43-1.15)
0.62 (0.37-1.05)
1.24 (0.74-2.06)
1.30 (0.77-2.21)
0.89 (0.57-1.41)
0.87 (0.54-1.41)
1.59 (1.09-2.32)
1.81 (1.22-2.70)
rs3758269
CC
CT
TT
CC
CT
TT
CC+CT
TT vs. CC+CT
Males
178/76
63/23
10/0
1.00
0.86 (0.49-1.48)
0.80 (0.44-1.46)
—
—
0.74 (0.43-1.27)
0.70 (0.39-1.26)
—
—
Females
278/88
96/21
7/3
1.00
0.69 (0.41-1.17)
0.59 (0.33-1.07)
1.35 (0.34-5.35)
1.32 (0.33-5.32)
0.74 (0.44-1.22)
0.65 (0.37-1.13)
1.47 (0.37-5.78)
1.47 (0.37-5.90)
(years)
177/68
68/19
10/0
1.00
0.73 (0.41-1.30)
0.54 (0.27-1.07)
—
—
0.63 (0.36-1.13)
0.48 (0.25-0.94)
—
—
>60(years)
279/96
91/25
7/3
1.00
0.80 (0.48-1.32)
0.78 (0.46-1.33)
1.25 (0.32-4.91)
1.25 (0.31-5.03)
0.83 (0.51-1.34)
0.82 (0.49-1.36)
1.31 (0.33-5.15)
1.32 (0.33-5.31)
249/71
79/28
6/0
1.00
1.24 (0.75-2.06)
1.06 (0.61-1.85)
—
—
—
0.98 (0.57-1.70)
—
—
≥25
207/93
80/16
11/3
1.00
0.45 (0.25-0.80)
0.40 (0.21-0.75)
0.61 (0.17-2.23)
0.65 (0.17-2.45)
0.47 (0.27-0.81)
0.43 (0.24-0.77)
0.72 (0.20-2.62)
0.79 (0.21-2.99)
Without central obesity
112/42
36/10
5/1
1.00
0.74 (0.34-1.62)
0.75 (0.32-1.77)
0.53 (0.06-4.70)
0.68 (0.07-6.19)
0.72 (0.34-1.52)
0.74 (0.33-1.68)
0.57 (0.07-4.99)
0.72 (0.08-6.51)
With central obesity
344/122
123/34
12/2
1.00
0.78 (0.51-1.20)
0.67 (0.42-1.07)
0.47 (0.10-2.13)
0.46 (0.10-2.13)
0.75 (0.49-1.45)
0.65 (0.41-1.03)
0.50 (0.11-2.25)
0.51 (0.11-2.34)
OR: odds ratio; CI: confidence interval. Adjusted for age, gender, systolic blood pressure, fasting glucose, total cholesterol, triglycerides, low-density lipoprotein cholesterol, course of hypertension, family history of hypertension, and family history of stroke.
